Health Catalyst, Inc.(HCAT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,757 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
HCAT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Health Catalyst, Inc. (HCAT), a Technology sector company. 13F Pro's AI-powered ranking engine scores HCAT at 21.9/100 on a 32-signal composite quality model, placing it at rank #2,757 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.1) and institutional flow (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Health Catalyst, Inc. reports quarterly revenue of $70.5M, net income of $-40.5M, free cash flow of $-70.0K. Top institutional holders of HCAT by reported 13-F value include First Light Asset Management, CDC Financial, Palogic Value Management, L.P., based on the most recent SEC filings. HCAT trades on the Nasdaq exchange and files with the SEC under CIK 1636422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Health Catalyst, Inc. directly from SEC EDGAR. Health Catalyst, Inc.'s 13F Pro composite quality score has ranged between 22 and 38 since 2021, currently 21.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$70.5M
Net Income
Q2 2026
$-40.5M
Free Cash Flow
Q2 2026
$-70.0K
ROIC
Q2 2026
-57.0%
D/E Ratio
Q2 2026
1.54
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1.5% YoYNet Income
-156.1% YoYOperating Income
-130.4% YoYEPS (Diluted)
-121.7% YoYTotal Assets
-41.5% YoYTotal Debt
-74.8% YoYOp. Cash Flow
-95.0% YoYFree Cash Flow
-101.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $311.1M +1.5% | $306.6M +3.6% | $295.9M +7.1% | $276.2M +14.2% | $241.9M +28.1% | $188.8M |
| Net Income | $-178.0M -156.1% | $-69.5M +41.2% | $-118.1M +14.0% | $-137.4M +10.3% | $-153.2M -33.2% | $-115.0M |
| Operating Income | $-160.9M -130.4% | $-69.8M +45.0% | $-126.9M +9.4% | $-140.0M +2.5% | $-143.7M -49.4% | $-96.1M |
| EPS (Diluted) | $-2.55 -121.7% | $-1.15 +45.0% | $-2.09 +20.5% | $-2.63 +18.6% | $-3.23 -11.0% | $-2.91 |
| Total Assets | $502.6M -41.5% | $858.9M +22.4% | $701.8M -6.7% | $752.3M -9.6% | $832.1M +44.0% | $577.7M |
| Total Debt | $154.9M -74.8% | $613.5M +169.1% | $228.0M +0.7% | $226.5M +25.2% | $180.9M +7.1% | $169.0M |
| Operating Cash Flow | $731.0K -95.0% | $14.6M +144.0% | $-33.1M +6.2% | $-35.3M -52.5% | $-23.1M +11.6% | $-26.1M |
| Free Cash Flow | $-237.0K -101.8% | $12.9M +137.7% | $-34.3M +8.3% | $-37.4M -11.5% | $-33.6M +1.0% | $-33.9M |
Get alerted when HCAT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Health Catalyst, Inc. including:
Top Institutional Holders of HCAT
First Light Asset Management, LLC
$25.5M12,810,861 shCDC Financial, Inc.
$14.1M7,092,698 shPalogic Value Management, L.P.
$9.8M4,922,442 shImpax Asset Management Group plc
$8.0M4,000,000 shNepsis Inc.
$5.9M2,976,187 shVANGUARD CAPITAL MANAGEMENT LLC
$5.9M2,971,598 shBlackRock, Inc.
$3.7M1,836,373 shWhetstone Capital Advisors, LLC
$3.0M1,515,000 shJANE STREET GROUP, LLC
$2.1M1,037,782 shDIMENSIONAL FUND ADVISORS LP
$1.8M911,819 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $25.5M | 12,810,861 |
| CDC Financial, Inc. | $14.1M | 7,092,698 |
| Palogic Value Management, L.P. | $9.8M | 4,922,442 |
| Impax Asset Management Group plc | $8.0M | 4,000,000 |
| Nepsis Inc. | $5.9M | 2,976,187 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.9M | 2,971,598 |
| BlackRock, Inc. | $3.7M | 1,836,373 |
| Whetstone Capital Advisors, LLC | $3.0M | 1,515,000 |
| JANE STREET GROUP, LLC | $2.1M | 1,037,782 |
| DIMENSIONAL FUND ADVISORS LP | $1.8M | 911,819 |
Companies Similar to HCAT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
SOUNDTHINKING, INC.
Expensify, Inc.
Definitive Healthcare Corp.
Shutterstock, Inc.
Inspired Entertainment, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put HCAT on your watchlist
Track score changes the day Health Catalyst, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HCAT a good stock to buy?
13F Pro's AI-powered analysis of Health Catalyst, Inc. (HCAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HCAT are available on the HCAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HCAT is classified as a small company.
Which hedge funds own HCAT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HCAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Health Catalyst, Inc.'s investment landscape.